What Ipamorelin is

Ipamorelin belongs to the growth-hormone-axis family of research peptides. The family divides cleanly into two mechanistic groups: GHRH analogues (Sermorelin, CJC-1295, Tesamorelin, Mod-GRF 1-29) that bind the GHRH receptor on somatotroph cells in the anterior pituitary, and GHRPs / ghrelin-mimetics (Ipamorelin, GHRP-2, GHRP-6, MK-677/Ibutamoren, Hexarelin) that bind the growth hormone secretagogue receptor (GHSR-1a). Combining one from each group synergistically amplifies pulsatile GH release above what either produces alone.

Mechanism of action

• GHRH analogues stimulate GH release via cAMP-dependent signaling in somatotrophs. They preserve the natural pulsatile pattern of GH secretion — a mechanistic advantage over exogenous rhGH.
• GHRPs / ghrelin-mimetics bind GHSR-1a, causing calcium-dependent GH release and simultaneously suppressing somatostatin (the negative regulator of GH). Ipamorelin is notable for GH-selectivity — it releases GH with minimal effect on cortisol, prolactin, or ACTH, which is why it appears frequently in the literature.

Downstream, GH drives hepatic IGF-1 production. Most of the anabolic and regenerative endpoints attributed to this class are IGF-1-mediated rather than direct effects of GH itself.

Published research findings

• Tesamorelin is FDA-approved for HIV-associated lipodystrophy; multiple published trials show reduction in visceral adipose tissue.
• Sermorelin was FDA-approved for pediatric GH-deficiency (later discontinued for commercial reasons, not safety).
• Ipamorelin and CJC-1295 are extensively studied in animal models of GH insufficiency and in academic pharmacokinetic studies.
• MK-677 (Ibutamoren) is an orally-bioavailable non-peptide ghrelin mimetic with published human PK data.

Dosing ranges reported in the literature

Doses reported in academic and industry protocols, provided as reference only:

• Sermorelin: 200–500 µg subcutaneous nightly.
• CJC-1295 (no DAC / Mod-GRF 1-29): 100 µg subcutaneous, up to three times daily around meals and pre-sleep.
• CJC-1295 with DAC: 1–2 mg subcutaneous weekly; DAC extends half-life through albumin binding.
• Ipamorelin: 100–300 µg subcutaneous, 1–3 times daily.
• Tesamorelin: 1–2 mg subcutaneous nightly.
• MK-677: 10–25 mg orally, once daily.

Timing in the literature emphasizes fasting-state administration — GH release is blunted by concurrent hyperglycemia and hyperinsulinemia, so protocols typically dose pre-sleep and inter-meal.

Stacking discussed in the literature

• CJC-1295 + Ipamorelin — the canonical GHRH + GHRP stack for pulsatile GH amplification.
• Sermorelin + Ipamorelin — similar pairing with a shorter-acting GHRH.
• Tesamorelin + Ipamorelin — for research protocols targeting visceral fat.

Considerations and reported effects

Water retention, transient injection-site erythema, and (with higher-dose GHRPs) hunger driven by GHSR-1a agonism are the most commonly-reported effects. Ipamorelin's cortisol/prolactin selectivity is why it appears more often than GHRP-2 or GHRP-6 in modern protocols.

Standard laboratory handling

Every research vial from PX1 is a lyophilized (freeze-dried) powder sealed under vacuum in a Type-I borosilicate vial with a butyl-rubber stopper and aluminum crimp seal. Correct handling preserves potency and prevents peptide-bond hydrolysis that degrades the active molecule.

• Storage before reconstitution: 2–8 °C refrigerator is ideal; freezer (−20 °C) for storage beyond six months. Short excursions to room temperature during shipping do not compromise integrity — the compound is stable in its solid state.
• Reconstitution solvent: bacteriostatic water for injection (0.9% benzyl alcohol) is standard for research protocols that require multiple sampling events from the same vial. Sterile water is acceptable for single-use protocols.
• Reconstitution technique: inject the diluent slowly against the vial wall — never directly onto the lyophilized cake. Swirl gently; do not shake. Shaking introduces air, denatures peptide secondary structure, and can create insoluble aggregates.
• Post-reconstitution storage: 2–8 °C refrigerated, typically stable 21–30 days depending on the peptide. Freezing a reconstituted solution repeatedly is not recommended — freeze/thaw cycles are the single biggest driver of loss-of-potency in the research literature.
• Concentration math: volume of diluent (mL) = peptide mass (mg) ÷ desired concentration (mg/mL). Example: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.

Purity, identity and COA verification

The single most important due-diligence step when sourcing Ipamorelin for research is reviewing the lot-specific Certificate of Analysis (COA). A credible COA contains:

1. HPLC purity value with chromatogram — target ≥ 98% for injectable-grade research peptides; ≥ 99% for the newest generation of GLP/incretin compounds. A single well-defined main peak with baseline separation from impurities is what you are looking for.
2. Identity confirmation by mass spectrometry — LC-MS or MALDI-TOF confirming the observed molecular weight matches the theoretical mass to within instrument tolerance.
3. Endotoxin (LAL / kinetic-chromogenic) result — expressed in EU/mg; USP guidance for parenteral products is well below 5 EU/kg body-weight equivalent, and reputable suppliers report < 10 EU/mg on the COA.
4. Sterility result — USP <71> membrane filtration or direct inoculation, both bacterial and fungal.
5. Karl Fischer moisture — target < 5% residual water for a properly lyophilized cake.
6. Residual-solvent screen — DMF, TFA, DCM, acetonitrile below ICH Q3C thresholds.

PX1 publishes lot-specific COAs at /purity-reports. If you have received a shipment and want to verify the exact lot documentation for Ipamorelin, cross-reference the lot number on the vial label to the COA PDF.

Why researchers choose PX1 for Ipamorelin

• 100% U.S. synthesis, lyophilization, and fill/finish. No repackaged imports. Every step from raw amino acid to sealed vial happens under one U.S. GMP-compliant roof.
• Third-party ISO-17025 testing on every lot. Purity, identity, endotoxin, sterility, moisture, and residual-solvent testing performed by an independent analytical laboratory whose data appears on the shipped COA.
• Chain-of-custody documentation from raw material through final QC — the same documentation package a clinical CDMO would provide.
• Same-day shipping on in-stock catalog items ordered before 3 p.m. ET, with insulated packaging and cold-pack where appropriate.

Common researcher questions

Q: How do I know the vial contents match the label? Compare the lot number on the vial to the lot number on the COA. The COA lists HPLC purity, identity by mass-spec, and endotoxin. If any of the three is missing or the lot doesn't match, don't proceed.

Q: Can I use bacteriostatic water past its printed expiration? Bacteriostatic water carries a manufacturer-assigned expiration for the sealed vial. Once punctured, USP guidance limits multi-dose vials to 28 days at 2–8 °C. Beyond 28 days, discard.

Q: Is refrigeration required during shipping? For most lyophilized peptides, no — the solid form is stable at ambient temperature for weeks. Some compounds (IGF-1 LR3, certain GH-releasing peptides) benefit from cold-chain shipping. PX1 uses insulated packaging for temperature-sensitive lines.

Q: What if the reconstituted solution is cloudy? Cloudiness indicates aggregation or precipitation and the solution should not be used. Common causes: over-vigorous shaking, incompatible diluent, or a vial that has passed its stability window.

Research use disclaimer

Ipamorelin is supplied to licensed research professionals for in vitro and in vivo laboratory research only. Products are not intended for human consumption, veterinary use, diagnostic use, therapeutic use, or as a food additive or cosmetic. Nothing on this page constitutes medical advice. Consult the primary literature — clinical-trial registrations, peer-reviewed publications — before designing any protocol. Compounds discussed here are investigational; several have not received FDA approval for any indication.

Additional PX1 references

• Complete research library
• Lot-specific purity reports
• Product catalog
• Manufacturing & QC standards